News stories about Cytori Therapeutics (NASDAQ:CYTX) have been trending somewhat positive on Monday, according to Accern. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cytori Therapeutics earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.3401937534409 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $38,000.00 in Stock (americanbankingnews.com)
- Bank Sa Swissquote Sells 72,630 Shares of Cytori Therapeutics Inc (CYTX) Stock (americanbankingnews.com)
- Today’s Hot Stock Under Review: Cytori Therapeutics Inc (NASDAQ: CYTX) – Alpha Beta Stock (alphabetastock.com)
- Investors need to focus on Analysts Rating: Cytori Therapeutics, Inc. (CYTX) – Wall Street Morning (wallstreetmorning.com)
- Sizzling Stock Alert: Cytori Therapeutics (CYTX) – Emn News (emnnews.com)
Shares of Cytori Therapeutics (NASDAQ CYTX) traded down $0.03 during midday trading on Monday, hitting $0.35. The stock had a trading volume of 1,921,600 shares, compared to its average volume of 3,448,922. The company has a market capitalization of $12.43, a price-to-earnings ratio of -0.39 and a beta of 2.72. Cytori Therapeutics has a one year low of $0.22 and a one year high of $2.13.
A number of brokerages have recently weighed in on CYTX. B. Riley reiterated a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th. Zacks Investment Research lowered Cytori Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Finally, Maxim Group set a $5.00 target price on Cytori Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th.
In related news, major shareholder Bank Sa Swissquote sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total transaction of $38,000.00. Following the sale, the insider now owns 5,496,655 shares of the company’s stock, valued at $2,088,728.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.90% of the company’s stock.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.